ResearcherUniversity of Tennessee Health Science CenterNo recent work listed
Saini Setua
Matched on ORCID iD 0000-0002-9874-6948; OpenAlex author ID A5018717567. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2017: 2 papers · 2018: 1 paper · 2019: 4 papers · 2020: 1 paper
Papers 8
- Novel Paclitaxel Nanoformulation Impairs De Novo Lipid Synthesis in Pancreatic Cancer Cells and Enhances Gemcitabine Efficacy. Co-author DOI 10.1021/acsomega.0c00793↗
- Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer. First author DOI 10.1016/j.biomaterials.2019.04.005↗
- Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. Co-author DOI 10.1016/j.nano.2019.102027↗
- Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer. Co-author DOI 10.1186/s13046-018-1009-7↗
- Gemcitabine Combination Nano Therapies for Pancreatic Cancer. First author DOI 10.3390/pharmaceutics11110574↗
- Clinical significance of MUC13 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2017.12.003↗
- Restitution of Tumor Suppressor MicroRNA-145 Using Magnetic Nanoformulation for Pancreatic Cancer Therapy. Co-author DOI 10.1007/s11605-016-3222-z↗
- miR-145: Revival of a Dragon in Pancreatic Cancer. Co-author PMID 28616589↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Meena Jaggi · 8 shared papers, 2017–2020 · strength 0.71
- Paper Novel Paclitaxel Nanoformulation Impairs De Novo Lipid Synthesis in Pancreatic Cancer Cells and Enhances Gemcitabine Ef… DOI 10.1021/acsomega.0c00793↗
- Paper Gemcitabine Combination Nano Therapies for Pancreatic Cancer. DOI 10.3390/pharmaceutics11110574↗
- Paper Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. DOI 10.1016/j.nano.2019.102027↗
- Murali Mohan Yallapu · 8 shared papers, 2017–2020 · strength 0.71
- Paper Novel Paclitaxel Nanoformulation Impairs De Novo Lipid Synthesis in Pancreatic Cancer Cells and Enhances Gemcitabine Ef… DOI 10.1021/acsomega.0c00793↗
- Paper Gemcitabine Combination Nano Therapies for Pancreatic Cancer. DOI 10.3390/pharmaceutics11110574↗
- Paper Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. DOI 10.1016/j.nano.2019.102027↗
- Subhash C. Chauhan · 8 shared papers, 2017–2020 · strength 0.71
- Paper Novel Paclitaxel Nanoformulation Impairs De Novo Lipid Synthesis in Pancreatic Cancer Cells and Enhances Gemcitabine Ef… DOI 10.1021/acsomega.0c00793↗
- Paper Gemcitabine Combination Nano Therapies for Pancreatic Cancer. DOI 10.3390/pharmaceutics11110574↗
- Paper Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. DOI 10.1016/j.nano.2019.102027↗
- Sheema Khan · 5 shared papers, 2017–2019 · strength 0.39
- Paper Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. DOI 10.1016/j.nano.2019.102027↗
- Paper miR-145: Revival of a Dragon in Pancreatic Cancer. PMID 28616589↗
- Paper Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer. DOI 10.1016/j.biomaterials.2019.04.005↗
- Bilal Bin Hafeez · 4 shared papers, 2019–2020 · strength 0.38
- Paper Novel Paclitaxel Nanoformulation Impairs De Novo Lipid Synthesis in Pancreatic Cancer Cells and Enhances Gemcitabine Ef… DOI 10.1021/acsomega.0c00793↗
- Paper Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. DOI 10.1016/j.nano.2019.102027↗
- Paper Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer. DOI 10.1186/s13046-018-1009-7↗
- Sonam Kumari · 4 shared papers, 2019 · strength 0.36
- Paper Gemcitabine Combination Nano Therapies for Pancreatic Cancer. DOI 10.3390/pharmaceutics11110574↗
- Paper Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. DOI 10.1016/j.nano.2019.102027↗
- Paper Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer. DOI 10.1186/s13046-018-1009-7↗
- Stephen W. Behrman · 3 shared papers, 2017–2019 · strength 0.22
- Paper Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer. DOI 10.1016/j.biomaterials.2019.04.005↗
- Paper Restitution of Tumor Suppressor MicroRNA-145 Using Magnetic Nanoformulation for Pancreatic Cancer Therapy. DOI 10.1007/s11605-016-3222-z↗
- Paper Clinical significance of MUC13 in pancreatic ductal adenocarcinoma. DOI 10.1016/j.hpb.2017.12.003↗
- Advait B. Shetty · 2 shared papers, 2019–2020 · strength 0.21
- Neeraj Chauhan · 2 shared papers, 2019 · strength 0.17
- Vivek Kumar Kashyap · 2 shared papers, 2019 · strength 0.17
- Andrew E. Massey · 2 shared papers, 2019 · strength 0.17
- Mohammed Sikander · 2 shared papers, 2017–2019 · strength 0.16
- Zachary E. Stiles · 2 shared papers, 2018–2019 · strength 0.15
- Kamalika Samanta · 1 shared paper, 2019 · strength 0.11
- Wěi Li · 1 shared paper, 2019 · strength 0.08
- Lei Wang · 1 shared paper, 2018 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.